Reddick manages fuel, wins regular-season finale at Las Vegas

first_imgLAS VEGAS – Tyler Reddick and his Richard Childress Racing team gambled and hit the jackpot Saturday evening at Las Vegas Motor Speedway, taking a chance on fuel mileage and racing just hard enough to hold off Christopher Bell by 0.738 seconds in the NASCAR Xfinity Series Rhino Pro Truck Outfitters 300.Reddick, who hoisted his fifth trophy, also officially earned the regular-season championship based on points come lap 71 of the 200-lap race. He was running fifth at the time.“Christopher Bell had a really fast race car today, but we were just able to come in and get fuel and tires and run really fast laps to keep us in front of him,’’ said Reddick, whose 30 laps led to close out the win were the sum of his laps out front. “Hats off to (crew chief) Randall (Burnett) and all the guys. We’ve had a really fast car in the past, unfortunately today we didn’t have it but we got them with strategy.’’RELATED: Official Las Vegas results | Reddick wins regular-season titleBrandon Jones was third, polesitter Cole Custer was fourth, and Justin Allgaier rounded out the top five. Veteran Elliott Sadler, a four-time Xfinity Series championship runner-up and 13-race winner, finished 10th in his last NASCAR national series race.It was a strong statement for Reddick, who earned his fifth victory to close out the regular season and now begins his playoff run on a high note Friday at Richmond Raceway. The Californian has a series-best 20 top-five and 22 top-10 finishes in 26 races and is the defending Xfinity Series champion.A six-race winner this season, Bell led a race-high 154 laps and was disappointed in the outcome after an especially strong showing. He pitted for tires and fuel with 30 laps remaining and returned to the track to try to make up Reddick’s nearly 20-second advantage at the time. Bell slowly gained but ultimately came up short.Although Bell’s effort didn’t earn him the race trophy, he does go into the playoffs with the points lead. He is the top-ranked driver with 2,055 points as they reset. Custer and Reddick are tied for second, 11 points fewer than Bell.The rest of the Xfinity Series postseason qualifiers in their reseeded order include Austin Cindric, rookie Chase Briscoe, veterans Justin Allgaier and Michael Annett, rookie Noah Gragson, Brandon Jones, Justin Haley, Ryan Sieg and rookie John Hunter Nemechek.Sieg failed post-race technical inspection, but it didn’t cost him a playoff berth.RELATED: Complete look at 12-driver playoff fieldCuster, who bested Bell for the pole position Saturday afternoon, earned his fourth consecutive top 10 at the track and, although disappointed not to win, seemed optimistic about his playoff potential.“We were just tight,’’ Custer said of his No. 00 Stewart-Haas Racing Ford. “We tried to make adjustments to fix it. Just a tough weekend. … We had a great regular season and looking forward to the playoffs. I’m pumped for it. I think all the tracks in the playoffs we’ll be strong and everybody should look out for us.’’In addition to Richmond, there’s the Charlotte Motor Speedway Roval and Dover International Speedway in the first round.Reddick’s crew chief conceded it was a risky move to get the victory, but Burnett ultimately said he was feeling the Vegas vibe and that a strategic gamble was the team’s only hope in besting the faster Bell.“We felt like we weren’t going to be able to get up there and compete with the 20; he was the class of the field all day,’’ Burnett said. “We saw an opportunity there. We knew we would be really close. None of the other guys came down (pit road). We really didn’t have anything to lose at this point.“We got back out there, (Reddick) did a great job managing and holding pace. We just managed our pace based on how fast the 20 was catching us. We had to pick it back up at the end.“It just worked out. “6.2.5last_img read more

Services today and death notices for Sept. 2

first_imgDeath noticesCharles A. Colichia Jr., 87, of Port Arthur died Wednesday, Aug. 31, 2016. Clayton Thompson Funeral Directors, Groves.Daniel “Danny” P. Gordy, 47, of Port Arthur died Wednesday, Aug. 31, 2016. Clayton Thompson Funeral Directors, Groves.Cody Lane Livingston, 23, of Beaumont, died Sunday, Aug. 28, 2016. Broussard’s, McFaddin Avenue, Beaumont. Jerry Lynn Fox, Melancon’s Funeral Home, Nederland, 2 p.m.Jolea Viguet, Hooks Cemetery, Kountze, 2:30 p.m. Services todayEvelyn Charles, Sacred Heart Catholic Church, Port Arthur, 11 a.m.Eunice Gobert, Harvest Time Bible Church, Port Arthur, 1 p.m.center_img Josef Alan Degen, 77, of Nederland died Thursday, Sept.1, 2016. Melancon’s Funeral Home, Nederland.Ramiro Ayala Villaneuva, 40, of Port Arthur died Tuesday, August 30, 2016. Gabriel Funeral Home.Marshal Lewis Dean, 85, of Beaumont died Thursday, Sept. 1, 2016. Broussard’s, Major Drive, Beaumont.last_img read more

Joe Iconis & Joe Tracz’s Be More Chill Will Transfer to Broadway

first_img This just might be the news of the day! Be More Chill, Joe Iconis and Joe Tracz’s fan-favorite musical currently making its off-Broadway debut at the Pershing Square Signature Center, will move to Broadway’s Lyceum Theatre in 2019. Previews will begin on February 13 followed by a March 10 opening night. Tickets are now on sale.”The fact that I get to make my Broadway debut as a writer surrounded by so many longtime collaborators and beloved friends both onstage and behind the scenes is a literal dream come true,” said Iconis in a statement. “Be More Chill has surprised me and Joe Tracz every step of the way and we can’t believe that our celebration of misfits, losers and underdogs gets to take up residence on 45th Street.”Based on the novel by Ned Vizzini, Be More Chill is the story of Jeremy Heere, your average, nothing-special teenager at Middleborough High in nothing-special New Jersey. That is, until the day he finds out about “The Squip.” Thus begins a journey that pits Jeremy’s desire to be popular against his struggle to remain true to his authentic self.Be More Chill features a book by Tracz and a score by Iconis. Stephen Brackett will repeat his work as director with Chase Brock as choreographer and Emily Marshall as musical director.The off-Broadway cast is led by Will Roland as Jeremy Heere, Jason Tam as “The Squip,” Gerard Canonico as Rich, Katlyn Carlson as Chloe, Stephanie Hsu as Christine, Lauren Marcus as Brooke, George Salazar as Michael, Jason SweetTooth Williams as Jeremy’s Dad/Mr. Reyes, Tiffany Mann as Jenna and Britton Smith as Jake.Broadway’s Be More Chill will feature scenic design by Beowulf Boritt, costume design by Bobby Frederick Tilley II, lighting design by Tyler Micoleau, sound design by Ryan Rumery and orchestrations by Charlie Rosen.Be More Chill was originally commissioned and produced by Two River Theater in Red Bank, New Jersey in 2015. Star Files View Comments Jason Tam & Will Roland in off-Broadway’s “Be More Chill”(Photo: Maria Baranova) Related Showscenter_img Show Closed This production ended its run on Aug. 11, 2019 Be More Chill Will Rolandlast_img read more

Vistancia Sees Record Sales for Planned Community

first_imgVistanciaa master planned community located in the rising foothills of the northwest Valley, is experiencing record sales for the first half of 2012 reporting 189 net sales representing a 78 percent increase in year-over-year sales growth.“We’ve eclipsed our 2011 total net sales during the first six months of this year and continue to attract premier builders to join our growing community,” said Mark Hammons, vice president/general manager of Vistancia.“It’s been an exciting year thus far and record sales growth coupled with an increase in builder activity is a confirmation that home builders and consumers have confidence in the market and consider Vistancia because of its unique lifestyle, wide selection of new home options and quicker access to Phoenix with the Loop 303 and Lone Mountain Parkway,” Hammons said.Visitors to the Vistancia Information Center have nearly doubled since 2011 setting a 96 percent year-over-year growth.Builder interest in the community is stronger than ever with three new builders opening in the first half of 2012 and up to five additional neighborhoods in The Village and Blackstone at Vistancia anticipated before year end. Specific builders and new homes planned will be announced this fall.“We’re seeing demand for new homes continuing to improve including our custom homesites and our most recent new builders like Meritage Homes, Taylor Morrison and Shea Homes have brought new buyers to the community,” said Hammons.“Each of our builders offer a different product and we anticipate that the newly-designed floorplans coming this fall will help satisfy the pent-up demand of consumers who have been waiting for new opportunities to purchase in Vistancia.”Set amongst a stunning backdrop of the natural Sonoran desert mountain beauty, the Vistancia community features a vibrant and genuine spirit with six actively selling new home neighborhoods by national and regional builders offering varied designs in three unique lifestyle communities: The Village at Vistancia, a multi-generational family community; Blackstone at Vistancia, a private golf community featuring luxury homes and custom homesites; and Trilogy at Vistancia, an active adult resort community.Recreational experiences at Vistancia include the 3.5-mile Discovery Trail, the heart of Vistancia that connects the entire community linking to on-site schools and scenic parks with interactive gardens and walkways for enjoying the surrounding Sonoran desert with year-round events.The centerpiece of The Village at Vistancia is the 15,000-square-foot Mountain Vista Club, featuring an outdoor basketball court, three swimming pools with waterslides, tennis courts, playground, large event lawn and picnic areas. Residents in The Village community can also enjoy the Foothills Center featuring a six-lane lap pool, children’s playground and scenic ramada.Amenities of Blackstone at Vistancia include a private guard gated entrance, neighborhood park and spectacular desert views. In addition, Blackstone at Vistancia features the Blackstone Country Club including a Jim Engh-designed 18-hole golf course and the Blackstone clubhouse, a 30,000-square-foot Spanish Colonial architectural style clubhouse with a 3,000-square-foot fitness center, three resort-style pools and lighted tennis courts. Club membership is separate from real estate purchase.Trilogy at Vistancia features an 18-hole golf course designed by Gary Panks and the 35,000-square-foot Kiva Club with fitness center, swimming pools, full-service Alvea Spa, four lighted tennis courts and the Verde Grill.“We’ve created a master plan that offers a wide range of living choices and amenities that engage residents, provides unique ways to discover their community and creates a genuine, overall feeling of being connected with our natural Sonoran desert beauty which is what today’s homebuyers are seeking,” Hammons said.Vistancia is located in Peoria set amongst a stunning backdrop of mountain ranges featuring dramatic views of White Peak, Twin Buttes and the Bradshaw Mountains in pristine desert surroundings.Vistancia now has a second community entrance and exit, providing both north and south access. Take Loop 303 to the new Lone Mountain Parkway (exit 127). The Vistancia Information Center is located at the guard-gated entrance of Blackstone at Vistancia. For more information about Vistancia visit www.vistancia.com or call 623-933-6233.last_img read more

Reading Pain in a Human Face

first_imgThe New York Times:How well can computers interact with humans? Certainly computers play a mean game of chess, which requires strategy and logic, and “Jeopardy!,” in which they must process language to understand the clues read by Alex Trebek (and buzz in with the correct question).But in recent years, scientists have striven for an even more complex goal: programming computers to read human facial expressions.…Jeffrey Cohn, a University of Pittsburgh professor of psychology who also conducts research on computers and facial expressions, said the CERT study addressed “an important problem, medically and socially,” referring to the difficulty of assessing patients who claim to be in pain. But he noted that the study’s observers were university students, not pain specialists.Dr. Bartlett said she didn’t mean to imply that doctors or nurses do not perceive pain accurately. But “we shouldn’t assume human perception is better than it is,” she said. “There are signals in nonverbal behavior that our perceptual system may not detect or we don’t attend to them.”Read the whole story: The New York Times More of our Members in the Media >last_img read more

Study: Cholera vaccine worked well during outbreak

first_imgThe idea of using cholera vaccines as a response tool got a boost today, with researchers reporting promising results during a 2012 outbreak in Guinea for Shanchol, one of two cholera vaccines that have been developed.In other cholera news, cases in Haiti in the first 3 months of this year were 75% lower than in the same period last year and the fewest since the epidemic began in 2010, according to a statement yesterday from the United Nations (UN).Overcoming vaccine perceptionsGlobal health officials have been hesitant to embrace the new cholera vaccines in outbreak settings, because they are traditionally thought of as being expensive, requiring multiple doses, and providing limited protection. However, recent vaccine trials have suggested the campaigns are worth considering.In new findings today, researchers from Doctors Without Borders (Medecins Sans Frontieres, or MSF) set out to test the short-term effectiveness of two doses of Shanchol, made by Shantha Biotechnics—an India-based subsidiary of Sanofi—for the first time in an outbreak. They published their findings in the New England Journal of Medicine (NEJM).Researchers have assessed the vaccine’s protection over the long term, but they haven’t measured its effect in the first months of vaccination. Though the other cholera vaccine, Dukoral, has shown good short-term protection and has already been used in the field in Asia and Africa, outbreak response officials are keenly interested in Shanchol’s performance, because it is much cheaper, doesn’t require buffer, and has a lower storage volume—all factors that would make it easier to deploy.The matched case-control study took place in Guinea, where mass vaccination campaigns, along with other response measures, targeted people in Boffa and Forecariah prefectures. Residents received two doses of Shanchol, 2 weeks apart, based on World Health Organization (WHO) recommendations.The team enrolled 40 case-patients who had lab-confirmed cholera infections, and compared vaccination rates with 160 age- and sex matched controls to determine vaccine effectiveness. They conducted face-to-face interviews to see if people had received the vaccine, and study participants were asked, if possible, to show their vaccine cards.Effectiveness estimated at 87%After adjusting for possible health-seeking behavior and information biases, they found that two doses provided significant protection against cholera, with a vaccine effectiveness of 86.6% (95% confidence interval, 56.7% to 95.8%). Researchers noted that the short-term protection level is on par with Dukoral and is reassuring, because other oral vaccines that have been tested in Africa have shown low levels of protection.Another reassuring finding was that Guinea’s cold-chain strategy didn’t seem to impair short-term protection. Health officials there store the vaccine in cold chain, but transport and use it at ambient temperature the day of vaccination.Only 25% of participants were able to show their vaccine cards, but the investigators said if they considered only participants who had their cards, vaccine effectiveness would still be 82%.During the outbreak, 316,250 doses of vaccine were given, with 48 patients reporting adverse reactions that were not severe. Vaccine coverage ranged from 69% to 84% in the areas where the vaccine campaign took place.The study results bolster the rationale for adding vaccines to cholera outbreak response and supporting global health efforts to build a vaccine stockpile for emergency use, the group concluded. They said more study is needed to determine protection afforded by a single vaccine dose.Part of comprehensive approach?In an editorial in the same issue of NEJM, two experts on Haiti’s cholera outbreak response wrote that a pilot program using oral cholera vaccines there alongside traditional response tools found that the vaccine could be effectively used as part of a comprehensive program. The authors are Jean William Pape, MD, and Vanessa Rouzier, MD, who are with GHESKIO (Haitian Study Group on Kaposi Sarcoma and Opportunistic Infections).Promising experiences with the vaccines helped sway the WHO’s policy that now supports vaccine use, though questions about Shanchol’s short-term effectiveness have been a challenge to fuller implementation, the commentators saidPape and Rouzier wrote that today’s study clearly shows the role that vaccines can play in curbing cholera epidemics.As vaccine stockpiles grow, some questions remain, such as prioritization when multiple outbreaks are under way and cost-effectiveness, they wrote. The two experts also said a study is under way to test the effectiveness of one dose, which, if effective, would reduce cost and logistics barriers.They also noted that it’s not yet clear if Shanchol—the cheapest and most easily administered vaccine—can be used in pregnant women and children younger than 1 year old.Declining cases in HaitiIn other cholera news, the UN commented on Haiti’s epidemic after a meeting of the High-Level Committee for the Elimination of Cholera in Haiti in Port-au-Prince this week.Along with the 75% reduction in cholera cases in the first trimester, the fatality rate was below the 1% target set by the WHO, the UN said. The agency didn’t specify the number of cases over the 3 months.Despite the improvement, Haitian Prime Minister Laurent Lamothe said cholera remains an emergency that demands the development of all possible control strategies, according the statement.The Haitian government’s 10-year plan to eliminate cholera requires $2.2 billion for large-scale development of public health and sanitation infrastructure. To support the most urgent activities, the UN said it is appealing for $70 million for the next 2 years, of which $34 million has been raised so far.Cases in South Sudan approach 600In other developments, a cholera outbreak that was recognized earlier this month in South Sudan had grown to 586 cases and 22 deaths as of May 25, the WHO Regional Office for Africa announced in a statement.The index case-patient in the outbreak got sick on Apr 23, and four cases have been confirmed in tests at the African Medical Research Foundation laboratory in Nairobi, Kenya. The nation’s health ministry declared the outbreak on May 15.Cases have been reported in 8 of 15 sub-counties in Juba County, the WHO said.”Given the on-going conflict and crisis situation in the country, the poor prevailing sanitary conditions, the beginning of the rainy season, and the history of cholera outbreaks in the country, the Ministry of Health of South Sudan continues to monitor the situation in Juba and surrounding areas,” the agency said.Luquero FJ, Grout L, Ciglenecki I, et al. Use of Vibrio cholerae vaccine in an outbreak in Guinea. N Engl J Med 2014 May 29;370(22):2111-20 [Abstract]Pape JM, Rouzier V. Embracing oral cholera vaccine—the shifting response to cholera. (Editorial) N Engl J Med 2014 May 29;370(22):2067-9 [Full text]See also:May 28 UN statementMay 27 WHO Africa statementlast_img read more

ASP Scan (Weekly) for Sep 02, 2016

first_imgOur weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans Four CRE cases reported in WisconsinOriginally published Sep 1.Investigators with the Centers for Disease Control and Prevention (CDC) today describe a small cluster of the worrisome “superbug” known as carbapenem-resistant Enterobacteriaceae (CRE) at two Wisconsin hospitals in Morbidity and Mortality Weekly Report (MMWR).According to the report, officials with the Wisconsin State Laboratory of Hygiene notified the Wisconsin Division of Public Health in June 2015 that five carbapenemase-producing CRE isolates had been identified among four inpatients at two hospitals in southeastern Wisconsin. They all contained the KPC gene, which codes for Klebsiella pneumoniae carbapemenase.The KPC-CRE isolates were identified among 49 isolates obtained from 46 patients from February to May 2015. The median age of the four patients (two men and two women) was 65, and median hospitalization length was 83 days. All four patients had been intubated and undergone a tracheostomy.Further investigation revealed that the five isolates exhibited a high degree of genetic relatedness but did not uncover how the bacteria traveled between the two facilities. Active surveillance conducted at the two hospitals in July 2015 identified no further cases. Site visits, reviews of infection prevention protocols, and interviews with infection prevention staff members, primary care providers, and patients found no breaches in recommended practices.The authors of the report say the findings demonstrate the importance of routine hospital- and laboratory-based surveillance for the detection of healthcare-related CRE. In this case, staff at neither of the two hospitals was aware of the possibility of CRE transmission among their patients. The authors also say the use of molecular subtyping methods (like whole-genome sequencing) to determine the genetic similarities in the isolates was particularly valuable.Sep 2 MMWR report ASP intervention not found to improve outcomes in C diff patientsOriginally published Sep 1.A study today out of the University of Michigan has found a real-time antibiotic stewardship program (ASP) intervention in patients with Clostridium difficile infection (CDI) improved process measures but did not improve outcomes.The study, published in the American Journal of Infection Control, details the results of what the authors call a “quasiexperimental” study of adult CDI patients before and after a real-time ASP review was initiated.In the intervention group (285 patients), an ASP pharmacist was called in after diagnosis to review each case with the medical team and make recommendations on optimal treatment, antibiotic therapy and acid-suppressing therapy, and surgical/infectious disease consultation. In the control group (307 patients), CDI treatment was left to the discretion of the patient’s primary medical team. Overall, ASP pharmacists provided treatment recommendations for 129 of the 285 patients in the intervention group.The primary measurement of the study was a composite of several outcomes—including 30-day mortality, intensive care unit admission, surgery, and CDI recurrence. But process measures that may influence outcomes in CDI patients were also measured, with researchers looking at whether acid-suppressive therapy was reduced in CDI patients and whether patients with severe CDI received infectious disease consultation and appropriate and timely antibiotic therapy.In the end, the researchers found that ASP intervention reduced unnecessary acid-suppressing therapy when compared with the control group. And patients with severe CDI who received ASP intervention were more likely to be treated with vancomycin, receive vancomycin therapy more quickly, and receive infectious disease consultation than the patients in the pre-intervention group. This finding is in line with previous studies on ASP intervention in CDI patients.However, the investigators were not able to demonstrate a statistically significant improvement in primary clinical outcomes among the patients who received ASP intervention. Occurrence of primary composite outcome was 14.7% in the pre-intervention group and 12.3% in the intervention groups. The authors of the study say this may be due to the low baseline rates of these outcomes among the patients.In conclusion, the authors say their findings, when added to previous literature on the topic, raise questions about whether ASP involvement in the conventional management of CDI is worthwhile, especially in institutions with low rates of CDI-attributable complications.Sep 1 Am J Infect Control study Study: Written reports help dentists reduce antibiotic prescribingOriginally published Aug 31.A new UK study has found that dentists prescribe fewer antibiotics to their patients after receiving a report on their past prescribing habits.According to the study, published yesterday in PLoS Medicine, dentists prescribe roughly 10% of the antibiotics dispensed in UK community pharmacies, often in the absence of clinical need. Using dental prescribing and treatment claim data routinely collected by the UK National Health Service (NHS), researchers with the RAPiD (Reducing Antibiotic Prescribing in Dentistry) trial set out to determine whether an individualized audit and feedback intervention could have an impact on prescribing habits.The trial included 795 dental practices in Scotland, with 632 practices in an intervention group and 163 in a control group. The intervention group was further subdivided into two groups: one that received a line graph showing an individual dentist’s monthly prescribing rate, and another that received a line graph with a written “behavior change” message containing national guidelines for dental antibiotic prescribing.At the start of trial, the rate of antibiotics prescribed per 100 NHS treatment claims was 8.3 in the control group and 8.5 in the intervention group. After 12 months, the researchers found that both groups were prescribing fewer antibiotics. But the drop in the prescribing rate in the intervention group—from 8.5 to 7.5—was 5.7% greater than it was for the control group. And the subset of dentists who received a written message saw their prescribing rate drop by an additional 6%.The authors of the study wrote that the findings are significant because they indicate that a “relatively straightforward, low-cost public health and patient safety intervention” could help the entire healthcare system address antimicrobial resistance.Aug 30 PLoS Med study Review outlines economic incentives for antibiotic developmentOriginally published Aug 31.Limited commercial returns are considered a primary factor in why pharmaceutical companies are not investing in antibiotic development. That’s why a “constellation of economic incentives” will be needed to promote antibacterial drug development going forward, according to an article published yesterday in Clinical Infectious Diseases.The article, written by members of the Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR), is a review of the various economic incentives identified in policy documents, peer-reviewed publications, organization proposals, and government-sponsored reviews that have addressed the question of how to spur new antibiotic development. In October 2015, TATFAR agreed to make an informed recommendation on a package of economic incentives to be considered and implemented in the future.In those documents, the authors found a consensus around the idea that economic incentives must contain both “push and pull” mechanisms that will guarantee return on investment. Push incentives include subsidies (in the form of grants, public-private partnerships, and tax credits) to fund early-stage development of antimicrobials, which is often risky and expensive. The idea is to provide incentives to academic institutions and companies by providing up-front money for research and development.Pull incentives, on the other hand, are meant to encourage antibacterial drug development by promising a substantial financial reward to companies that successfully develop new antibiotics. Examples include large milestone or prize payments, patent buy-outs, advanced market commitments, and extended market exclusivity.Pull incentives, the authors found, will be most successful if they rely on a “de-linkage” model that would remove the motivation for pharmaceutical companies to market and oversell their product. Negating the need for high product sales, they argue, would ensure that new antibiotics are not overused, thereby linking new antibiotic development to conservation and stewardship.Finally, the authors found widespread agreement that global coordination will be needed to administer the funding of these incentive programs. Aug 30 Clin Infect Dis literature review Growing polymyxin resistance reported in CRE in BrazilOriginally published Aug 31.Brazilian researchers are reporting increasing resistance to polymyxin antibiotics in clinical Klebsiella Pneumoniae strains that are already resistant to carbapenem antibiotics.In a letter to Emerging Infectious Diseases, the researchers report on an analysis of more than 3,000 K pneumoniae isolates recovered from patients at 10 private tertiary-care hospitals in Sao Paulo from January 2011 to December 2015.The analysis showed a dramatic increase in carbapenem resistance in the K pneumoniae isolates—from 6.8% in 2011 to 35.5% in 2015. And among the carbapenem-resistant K pneumoniae isolates, polymyxin resistance rose from 0% in 2011 to 27.1% in 2015. Polymyxin resistance among carbapenem-susceptible K pneumoniae isolates also rose, from 0.7% in 2011 to 3.9% in 2015.The authors said the findings are worrisome because carbapenem-resistant Enterobacteriaceae (CRE) are more deadly than carbapenem-susceptible strains, and carbapenem-resistant K pneumoniae bacteria are endemic in Brazil. Furthermore, most resistant infections are treated with polymyxins.Aug 30 Emerg Infect Dis letter UN experts warn antibiotic resistance will put mothers, infants at riskOriginally published Aug 30.Every year, more than 30,000 women and 400,000 newborns die from infections that occur shortly after a woman has given birth. And those numbers will likely grow as rising drug resistance renders antibiotics less effective.That’s the central message in a commentary yesterday by Anthony Costello, MD, WHO director of maternal, newborn, child, and adolescent health, and Stefan S. Peterson, MD, PhD, MPH, UNICEF chief of health. The global health experts write that overuse of antibiotics in humans, along with “needless use” in animals, has created a “recipe for disaster” by accelerating the process in which exposed microbes build resistance.Antibiotic resistance, they say, will have a major impact on newborns, who lack fully developed immune systems and are therefore more susceptible to infections they might pick up from their mother or from the hospital. Even more at risk will be children born in low-income countries, where healthcare facilities often lack basic sanitary conditions and lifesaving antibiotics are scarce.”More children in Africa die from a lack of access to antibiotics than from antibiotic-resistant infections,” Costello and Peterson write. “Indeed, many still die from infections, such as bacterial pneumonia, that should be easily treatable.”To solve this problem of “access and excess” and save the lives of infants and mothers, Costello and Peterson write, healthcare providers need to begin by stopping the spread of infection and negating the need for antibiotics. This means that all healthcare facilities must have running water and basic sanitation, and that staff must follow good hygiene practices. They also recommend implementing policies to discharge mothers and newborns from the hospital sooner, in order to reduce exposure to infectious microbes.And lastly, healthcare providers should use antibiotics only when they can confirm that they are absolutely needed. “Simply put, those who need lifesaving antibiotics must get them, and those who do not must not,” they write.Aug 29 WHO commentary MCR-1 found for the first time on the Arabian PeninsulaOriginally published Aug 29.An international team of researchers is reporting the first case of the colistin-resistance gene MCR-1 on the Arabian Peninsula.In a study published in the International Journal of Infectious Diseases, the researchers reported that out of 75 colistin-resistant Enterobacteriaceae strains isolated from clinical cases in Bahrain, Kuwait, Oman, Saudi Arabia, and the United Arab Emirates, 4 Escherichia  coli isolates were found to harbor the MCR-1 gene on mobile pieces of DNA known as plasmids. Two of the isolates were from blood samples; the two others were from urine and a bed sore.The researchers noted that the plasmids on the four isolates all carried various genes that confer resistance to carbapenem and beta-lactam antibiotics, with one of the isolates expressing high levels of carbapenem resistance. Besides colistin—which is considered an antibiotic of last resort—all four strains were uniformly resistant to third-generation cephalosporins, tetracycline, trimetoprime/sulfamethoxasole and gentamicin.The researchers also said that one of the plasmids identified is the first found in a human E coliisolate to carry both MCR-1 and resistance genes to other classes of antibiotics. The findings are a concern because they suggest antibiotics commonly used in humans could facilitate the spread of MCR-1-carrying bacteria.The MCR-1 gene was first identified in China in 2015, when researchers detected its presence in E colisamples from food, food animals, and humans. Since then, it’s been found in bacteria in more than 30 countries.Aug 26 Int J Infect Dis study  British scientists warn about drug-resistant fungal infectionsOriginally published Aug 29.UK scientists say that fungal infections are becoming increasingly resistant to the drugs used to treat them and warn that deaths will likely increase with rising resistance.Fungi can cause a host of illnesses, from minor skin infections such as ringworm to more dangerous conditions like valley fever. While many of these conditions can be treated easily, fungal infections become more of a threat when they occur in people with compromised immune systems, like cancer patients, HIV patients, and premature babies. They’re also a bigger problem in developing nations.The Guardian reports that UK doctors are becoming increasingly alarmed about rising resistance to a class of antifungal agents known as azoles, which are used to treat a variety of fungal infections. Fungal resistance is similar to antibiotic resistance, but experts say it may be even more worrisome because there are far fewer drugs to treat fungal infections than there are antibiotics to treat bacterial infections.”We cannot afford to lose the few drugs we have—particularly as very little funding is being made available for research into fungi and fungal infections,” said Adilia Warris, MD, co-director of the Centre for Medical Mycology at Aberdeen University.Warris and other experts said the widespread use of fungicides on agricultural crops is one of the factors in rising fungal resistance.Fungal infections take more than 1.3 million lives each year globally, according to Rutgers University scientists.Aug 26 Guardian storyDec 23, 2013 Rutgers news release “Attacking fungal infection, one of world’s major killers”last_img read more

UNM-LA Advisory Board Votes For No Tuition Increase In 2021 And Expansion Of Mechanical Engineer Degree Program

first_imgLANL Senior Director Nan Sauer of the Partnerships and Pipeline Office talked to the UNM-LA Advisory Board about a collaboration bringing a Bachelor of Science in Mechanical Engineering degree program to UNM-LA. Photo by Nancy Coombs/ UNM-LAUNM-LA student Allan VanCleave is recognized as one of two UNM-LA students honored as Phi Theta Kappa Scholars during the 2020 New Mexico Legislative Session. Photo by Nancy Coombs/UNM-LAUNM-LA News:At the UNM-Los Alamos (UNM-LA) Advisory Board meeting Monday, March 3, in addition to the board’s recommendation on tuition and fees, advisory board members had the opportunity to hear from Los Alamos National Laboratory (LANL) Senior Director Nan Sauer of the Partnerships and Pipeline Office.Sauer talked to the UNM-LA Advisory Board about collaborations between LANL and UNM-LA regarding programs to help support local workforce needs.Last fall, LANL, UNM School of Engineering and UNM-LA collaborated to develop a pathway for students to complete a Bachelor’s Degree in Mechanical Engineering on the UNM-LA campus, which will provide an opportunity for LANL employees, UNM-LA students and others to continue their education locally. Sauer mentioned that more than 125 LANL employees expressed an interest in the program.Students would complete the Associate’s Degree in Pre-Engineering at UNM-LA. The UNM School of Engineering plans to start offering upper division classes on the UNM-LA campus in Fall 2020. Students interested in the Mechanical Engineering program should contact Irina Alvestad at 505.661.4696 or email irina@unm.edu.The Advisory Board recommended no increase in tuition and fees for 2020-21, following the proposal by the UNM-LA Executive Team. The recommendation was based on expectations of revenues and expenditures for next year. For further information about the UNM-LA Advisory Board, visit losalamos.unm.edu/faculty-staff/administration/advisory-board/.UNM-Los Alamos is an innovative, rigorous, and affordable comprehensive branch community college that provides foundations for transfer, leading-edge career programs, and lifelong learning opportunities. More information about UNM-LA is available at losalamos.unm.edu.UNM-LA student Aaliyah Sandoval, right, was introduced to the board members as a recipient of a recent N3B scholarship. Her mother, Dana also attended the meeting. Photo by Nancy Coombs/UNM-LAUNM-LA Board members from left, Laura Burrows, David Sutton and Steve Boerigter review material during the meeting. Photo by Nancy Coombs/UNM-LAlast_img read more

Geotech expands hire fleet

first_imgSubscribe Get instant access to must-read content today!To access hundreds of features, subscribe today! At a time when the world is forced to go digital more than ever before just to stay connected, discover the in-depth content our subscribers receive every month by subscribing to gasworld.Don’t just stay connected, stay at the forefront – join gasworld and become a subscriber to access all of our must-read content online from just $270.last_img